суббота, 24 декабря 2016 г.

FDA approves Biogen drug for lead genetic cause of infant death

FDA approves Biogen drug for lead genetic cause of infant death


Dec 23 The U.S. Food and Drug Administration on Friday said it has approved Biogen Inc's drug to treat spinal muscular atrophy, the leading genetic cause of death in infants. The drug, nusinersen, which was discovered by Ionis Pharmaceuticals and licensed to Biogen, will be sold under the brand name Spinraza.



from Biotech News